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ABSTRACT  
Context: Puberty is associated with 
increased testicular testosterone (TT) 
synthesis, which is required to trigger 
spermatogenesis and to repress anti-
Mullerian hormone (AMH) production. 
However, testicular gonadotropin 
stimulation during fetal and newborn life 
neither initiates spermatogenesis nor 
represses AMH. 
Objective: We postulated that a lack of 
androgen receptor (AR) expression in 
Sertoli cells (SC) might explain why these 
processes do not occur during early human 
development. 
Methods and patients: Using 
immunohistochemistry and quantitative 
PCR we examined the relationship 
between AR, AMH and FSH receptor 
(FSHR) expression in fetal, newborn and 
adult human testis. The ability of T to 
repress AMH secretion was evaluated in 
male newborns, neonates and two adults 
with androgen insensitivity syndrome 
(AIS) and also in vitro using SMAT1 
Sertoli cells. 
Results: FSHR was present in SC at all 
developmental stages. In fetal and newborn 
testis, AR was expressed in peritubular and 
Leydig cells but not in SC. This coincided 
with the absence of spermatogenesis and 
with strong SC AMH expression. In adult 
testis, spermatogenesis was associated with 
AR expression and with a decrease in SC 
AMH content. Accordingly, AR mRNA 
expression was lower and AMH mRNA 
expression higher in fetal testes than in 
adult testes. In AIS patients combined 
gonadotropin stimulation induced an 
increase in circulating T and AMH, a 
finding consistent with a failure of TT to 
repress AMH in the absence of AR 
signalling. Finally, direct androgen 
repression of AMH only occurred in AR-
expressing SMAT1 cells. 
Conclusion: Functional androgen 
receptors are essential for TT-mediated 
AMH repression in Sertoli cells. 
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INTRODUCTION 
 
In the human adult testis, spermatogenesis 
is under the control of two gonadotropins, 
namely follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH). FSH acts 
directly on Sertoli cells (SC), while LH 
induces testosterone (T) production after 
Leydig cell stimulation. Intratesticular 
testosterone (TT) acts via a paracrine 
mechanism on androgen receptors (AR) 
expressed by target cells situated in the 
seminiferous tubules. In adulthood, the 
action of androgens on the seminiferous 
tubules is essential for full, quantitatively 
normal spermatogenesis and fertility. Most 
evidence suggests that this effect is 
mediated through an effect on SC, 
although the precise mechanisms are 
unclear. Recently, spermatogenesis was 
found to be arrested in mice specifically 
lacking AR in their SC (1-3).  
Anti-Mullerian hormone (AMH) is 
produced by SC from fetal life until 
puberty and is responsible for Mullerian 
duct regression in male fetuses. AMH and 
T serum levels correlate negatively during 
puberty and adulthood, indicating that TT 
is responsible for inhibiting SC AMH 
production. This was confirmed in adult 
congenital hypogonadotropic 
hypogonadism (CHH) patients, whose 
testicular AMH secretion is inhibited by 
both hCG and androgen administration (4, 
5). 
AMH and T levels are both high during 
fetal and neonatal life (6, 7), indicating that 
testicular T is unable to repress AMH 
during these periods.  
One important physiological issue is why 
the human testis is unable to produce 
sperm and to repress AMH secretion 
during fetal and neonatal life, despite 
stimulation by chorionic and pituitary 
gonadotropins, respectively. The aim of 
this study was to test the hypothesis that 
the absence of spermatogenesis and the 
AMH repression observed during human 
fetal and newborn life are related to the 
absence of AR in SC, despite FSH receptor 
(FSHR) expression. For this purpose, we 
compared the expression profiles of AR, 
FSHR and AMH proteins and their 
messenger RNAs in human fetal, newborn 
and adult testes by means of 
immunohistochemistry and real-time 
quantitative PCR (qPCR). In addition, we 
compared T and AMH levels in umbilical 
arterial cord blood of male newborns, 20- 
to 30-day-old neonates, and adults with 
normal or altered androgen sensitivity, in 
order to evaluate the ability of T to repress 
AMH secretion. Our results clearly 
demonstrate that in humans, AR 
expression in Sertoli cells is required both 
to induce spermatogenesis and to repress 
AMH. 
 
MATERIALS AND METHODS 
 
Tissues collection and quality 
 
Archival paraffin-embedded human 
testicular samples were collected at 
different stages of development. Archival 
fetal testis samples (n=46), collected at 14 
to 35 weeks of gestation, were selected 
from the organ bank of the Pathology 
Institute of Bari University with local 
ethics committee approval. Newborn 
(n=10) and adult (n=10) human testis 
samples were collected between 2 days and 
6 months and between 20-40 years of age, 
respectively. These samples were obtained 
from the licensed collections of three 
pathology departments (Bicêtre, Créteil 
Intercommunal and Necker-Enfants 
Malades Hospitals, Paris). Snap-frozen 
testis specimens from 9 human fetuses of 
16 to 38 weeks and from adult men were 
also obtained from the same licensed tissue 
collection (French Bioethics law n° 2004-
800). 
The fetal samples originated from fetuses 
that had died in utero and had been rapidly 
delivered and autopsied within 24-36 h 
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postmortem. None of the terminations 
were performed for fetal abnormalities. 
Tissue integrity was demonstrated as 
described in (8). Neonatal testis samples 
were obtained from cases of sudden infant 
death, and adult samples were obtained 
from men undergoing surgical 
investigation for obstructive azoospermia. 
The selected samples had a normal 
karyotype (46 XY) and normal 
macroscopic and histological features.  
 
Immunohistochemistry  
Briefly, 5-µm-thick tissue sections were 
deparaffinized and rehydrated in 
successive baths of toluene and graded 
alcohol solutions. Slides were then 
subjected to microwave antigen retrieval 
for 15 min in pH 6 citrate buffer. For 
FSHR immunostaining the sections were 
preincubated with ready-to-use proteinase 
K (DakoCytomation, Carpinteria, CA) for 
10 min at room temperature prior to 15 
min of microwaving at full power in Tris–
EDTA buffer pH 9. Slides were incubated 
overnight at 4°C with the following 
primary antibodies: anti-3-β-
hydroxysteroid-dehydrogenase (3 βHSD) 
(kind gift from Prof. Van-Luu The, Laval 
University, Canada), anti-AMH (9), anti-
FSH receptor (FSHR 323) (10) and anti-
androgen receptor (sc-816, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) at 
1:2000, 1:1000 and 1:50 dilution, 
respectively. Bound immunoglobulins 
were revealed with a streptavidin-biotin-
peroxidase-aminoethylcarbazole kit 
(LSAB+, DakoCytomation). 
 
RT- PCR  
Total RNA was isolated from frozen 
samples with the TRIZOL reagent 
(Invitrogen, Cergy Pontoise, France) as 
recommended by the manufacturer. RNA 
integrity was checked on agarose gel 
before processing for RT-PCR as 
previously described (8) 
 
Real-time RT-PCR 
Specific AMH and AR gene expression 
was quantified by real-time PCR (see 
Supplemental Table 1 for primers). Total 
RNA, extracted as described above, was 
retrotranscribed and amplified on an ABI 
7300 Sequence Detector (Applied 
Biosystems, Foster
 
City, CA) as previously 
described (8). Ribosomal 18S RNA was 
used as the internal control for data 
normalization. Results are means ± SEM 
of at least two independent analyses of at 
least two different reverse-transcribed 
samples. The relative expression level of 
each gene is expressed relative to 18S 
RNA (attomoles of specific gene per 
femtomole of 18S).  
 
T and AMH measurements in umbilical 
cords of male newborns, neonates and 
adults 
Neonatal blood samples were obtained 
from umbilical cords arteries of 17 full- 
term eutrophic male newborns 
immediately after delivery. Written 
informed consent was obtained from the 
mothers. The study was conducted in 
accordance with the Declaration of 
Helsinki and after approval from the local 
ethics committee. Blood samples were also 
obtained between day 20 and 30 of life 
from 21 normal boys with intrascrotal 
testes, and from 20 normal fertile males 
aged 17-37 years being evaluated in the 
context of female partner infertility. This 
part of the study was also approved by the 
local ethics committee, and we only used 
surplus serum taken for diagnostic 
purposes. Plasma testosterone (T) was 
measured with a commercial RIA method 
with a detection limit of 0.06 ng/ml (0.19 
nmol/l) and intra- and interassay variation 
coefficients of 5.8% and 8.0%, 
respectively. Serum AMH levels were 
measured with an ELISA method 
(AMH/Mullerian-inhibiting substance 
ELISA, Immunotech-Beckman, Marseille, 
France), as previously described (4). The 
detection limit was 0.7 pmol/L (0.1 ng/ml), 
and the intra- and interassay coefficients of 
variation were 5.3% and 8.7%, 
respectively, for a serum AMH 
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concentration of 35 pmol/l and 4.9% and 
7.8% for a serum AMH concentration of 
1100 pmol/l.  
 
Clinical investigation of men with 
moderate androgen insensitivity syndrome 
(MAIS) or congenital hypogonadotropic 
hypogonadism (CHH)  
We analyzed testicular responses to 
combined human gonadotropins in two 
azoospermic MAIS patients by comparison 
with 10 CHH patients receiving 
gonadotropin combination therapy with 
hCG (Organon, Puteaux, France) and 
rhFSH  (recombinant human FSH) (Gonal-
F®, Serono, Aubonne, Switzeland) at 
respective doses of 1500 IU and 150 IU, 
three times a week, for infertility.  
MAIS patient #1, who was hemizygous for 
the M780I mutation of the AR gene, has 
been described in detail elsewhere (11). 
MAIS patient #2, a Caucasian boy, was 
first seen at 19 years of age with bilateral 
gynecomastia and impaired virilization but 
no hypospadias. Testicular volume was 10 
ml bilaterally (normal range 15-30 ml), the 
penis was less than 4 cm long and his 
pubic hair was at Tanner stage III. His total 
plasma T level was 13.4 ng/mL (normal, 
3.2–9.7 ng/mL, x 3.467 = nmol/L), and his 
LH was 14.8 IU/L (normal, 4–7 IU/L). 
Analysis of two semen samples showed 
azoospermia. The previously reported A to 
G transition (12) was found in exon 8 at 
nucleotide position 2973 causing an 
unconserved arginine residue to be 
replaced by a glycine  (R871G). 
Ten previously untreated men, aged 18–31 
years, with idiopathic
 
CHH (n=5) or 
Kallmann syndrome (n=5),
 
were selected 
for diagnosis and choice
 
of therapy. The 
diagnostic criteria for CHH were as 
reported elsewhere (4, 5, 13, 14). None of 
the patients had a history
 
of 
cryptorchidism. All had low circulating T 
and gonadotropin levels. None had 
previously
 
received gonadotropin or 
androgen replacement therapy. The 
patients were offered treatment consisting 
of FSH combined with hCG in order to 
increase testicular size, virilization and 
fertility as previously reported (4, 5, 13).  
All the subjects gave their informed 
written consent to participate in the
 
study, 
which was approved by the local ethics 
committee. Treatment was always well 
tolerated and compliance, evaluated by 
measuring circulating FSH and T levels, 
was excellent (see Results). AMH was 
assayed in blood to evaluate the testicular 
response. In MAIS and CHH patients, 
blood samples were drawn before 
treatment and every month during 
combined
 
treatment; hormone 
measurements were performed in a single 
assay. 
 
Cells culture and transfection 
SMAT1 cells were cultured as described in 
(15). Cells were seeded at a density of 2 x 
10
5
 /well
 
in six-well plates and transiently 
transfected with 1 µg
 
of human AR 
expression vector (hAR-pcDNA3)
 
using 
the Lipofectamine reagent (Invitrogen, 
Carlsbad, CA92008). In
 
brief, one day after 
initial plating, DMEM with 10% fetal calf 
serum
 
was replaced by DMEM with 
Dextran-coated charcoal treated serum.,
 
Transfections were performed 24 h later. 
Fresh medium containing 10
-5
M forskolin 
alone or combined with 10
-7
M 
dihydrotestosterone was added
 
to the cells 
for 24 h. The cells were then rinsed twice 
with PBS and processed for RNA 
extraction and real-time PCR as described 
above. 
 
Western blot analysis and 
immunoprecipitation assay 
Total protein extracts were prepared from 
SMAT1 cells transiently transfected or not 
with hAR-pcDNA3. Immunoprecipitation 
was performed by incubating 0.5 mg of 
total proteins with 1 µg of anti-AR 
antibody (sc-816, Santa-Cruz) overnight at 
4°C. Immunoprecipitates were purified 
with protein A Sepharose CL-4B beads, 
and submitted to Western blot analysis 
using the same antibody at 1:200 dilution, 
followed by incubation with a peroxidase-
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conjugated goat anti-rabbit antibody 
(1:15000, Vector Laboratories, 
Burlingame, CA). The blots were 
visualized with the ECL+ detection kit (GE 
Healthcare). 
 
RESULTS 
 
3βHSD expression in human testis 
We first examined the immunoexpression 
pattern of the key enzyme 3βHSD in order 
to evaluate the steroidogenic activity of 
Leydig cells. As expected, the protein was 
located in the cytoplasm of Leydig cells in 
all fetal (Fig. 1A), newborn (Fig. 1B) and 
adult (Fig. 1C) testicular samples.  
 
Immunohistochemical detection of AR 
and AMH in human testis  
To determine the time course of AR and 
AMH expression during human testicular 
development, which might account for the 
relative testosterone resistance of SC, we 
compared AR and AMH expression in 
fetal, newborn and adult testes. In fetal and 
newborn testes, AR protein was detected in 
Leydig and myoid peritubular cells, but not 
in germ cells or SC (Fig. 1D and 1E). The 
absence of AR in SC coincided with very 
strong AMH expression in the same cells 
of all fetal and neonatal testis samples (Fig. 
1G  and 1H). In contrast, in all adult 
human testis samples examined, AR was 
detected not only in Leydig cells and 
myoid peritubular cells but also in SC (Fig. 
1F), whereas AMH was not expressed 
(Fig. 1I). Semi-quantitative results for AR 
and AMH expression during human testis 
development are summarized in Table 1. 
 
AR and AMH mRNA levels in human 
fetal testis 
To examine quantitative changes in AMH 
and AR expression during testis 
development, mRNA levels of these genes 
were determined by real-time quantitative 
PCR in 10 fetal testes obtained at 16 (n= 
2), 20 (n=1), 21 (n=1), 22 (n=1), 24 (n=2), 
25 (n=2) and 38 (n=1) weeks of gestation, 
by comparison with adult testes (Fig. 2). 
The relative expression level of AR mRNA 
in fetal testis was 30% or lower than that in 
adult testis (Fig. 2A). This difference was 
probably due to the absence of AR 
expression in fetal testis SC. We then 
examined AMH mRNA expression and 
found that levels were 2- to 30-fold higher 
in fetal than in adult testes (Fig. 2B). Thus, 
the AR/AMH mRNA ratio, an index of AR 
expression in SC, was 151 ± 8 in adult 
testis, compared to 1-20 in fetal testis, in 
keeping with the lack of AR 
immunoexpression in fetal SC. 
 
FSHR expression in human testis 
To determine whether the lack of 
spermatogenesis in the fetal and newborn 
testes is related to the lack of FSHR during 
these periods of life, we studied FSHR 
expression by immunohistochemistry and 
RT-PCR. As shown in Fig. 3A-C, FSHR 
immunoreactivity was localized to the SC 
membrane in fetal, newborn and adult 
testis. Furthermore, we confirmed that, as 
in adult testis, FSHR mRNA is also 
detected in human fetal testis (Fig. 3D). 
Using FSHR as another SC marker, we 
confirmed that the AR/FSHR mRNA ratio 
is higher in adult testis (406 ± 25) than in 
fetal testis (7.5 ± 1.5), providing additional 
support for the lack of AR expression in 
SC during human fetal development.
 
Inability of combined gonadotropin 
stimulation to repress AMH in adult 
patients with an AR signaling defect 
We then compared the testicular responses 
to combined hCG and rhFSH in two adult 
MAIS patients and 10 CHH patients used 
as positive controls of preserved AR 
signaling in post-pubertal testes (Fig. 4A 
left panel). As expected (4, 5) 
gonadotropin therapy increased the serum 
levels of FSH (from 0.6 ± 0.3 to 11.2 ± 2.2 
IU/L) and T (from 0.46 ± 0.2 to 5.8 ± 2.2 
ng/ml) in CHH patients leading to a 
concomitant collapse of AMH levels (from 
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406 ± 274 to 37 ± 18 pmol/L; P<0.001) 
which reached normal adult levels (Fig. 
4A, right panel). In contrast, in MAIS 
patients, despite a further increase in their 
plasma T levels induced by gonadotropin 
administration (from 11-13.4 to 15-19.4 
ng/ml), the serum AMH level also rose, 
clearly demonstrating that, in these adult 
patients, testicular T is unable to repress 
AMH secretion in the absence of 
functional AR and therefore to prevent the 
AMH stimulation induced by rhFSH. This 
response pattern was similar to that 
observed during the prenatal and postnatal 
period in which, despite relatively high 
circulating T levels driven by chorionic 
and pituitary gonadotrophin stimulation, 
mean AMH levels remain significantly 
higher than in post-pubertal men (6) (Fig. 
4A, right panel). Interestingly, AMH levels 
were significantly higher in 20- to 30-day-
old boys than in newborns, a finding 
consistent with our demonstration of FSHR 
expression in SC and its stimulation by 
FSH during the early post-natal period 
(16). In addition, strong AMH 
immunostaining was observed in SC of 
both adult patients with AIS and untreated 
CHH patients (Fig. 4B), contrasting with 
undetectable AMH expression in adults 
with normal testicular T and androgen 
sensitivity (see Fig. 1 panel I). 
Collectively, our results clearly indicate 
that repression of AMH secretion requires 
both an appropriate intratesticular T levels 
and functional AR signalling in SC. 
AMH repression by androgens requires 
functional androgen receptors in SMAT1 
cells  
To investigate direct androgen regulation 
of AMH in a Sertoli cell model, we 
examined endogenous AMH expression by 
means of real-time PCR in SMAT1 cells, 
an immortalized immature Sertoli cell line 
which does not express AR (Fig. 5A). 
Forskolin induced a 2.5-fold increase in 
AMH expression (Fig. 5B) through a PKA-
dependent mechanism, as already reported 
(15). However, coadministration of 
dihydrotestosterone did not affect 
forskolin-induced AMH expression. In 
contrast, when SMAT1 cells were 
transiently transfected with a human AR 
expression vector (Fig. 5A and C), 
forskolin-stimulated AMH mRNA levels 
returned to basal values after 
dihydrotestosterone exposure, providing 
the first evidence that functional AR are 
crucial for full AMH repression by 
androgens in Sertoli cells.  
 
DISCUSSION  
 
The role of androgen receptor (AR) in 
spermatogenesis has been the subject of 
intense interest for many years. Multiple 
rodent studies of androgen withdrawal and 
disruption of AR activity by surgical, 
chemical or genetic means have produced 
convergent results: spermatogenesis rarely 
occurs in the absence of androgens and 
functional AR. It has been assumed that 
the main cellular mediator of this 
regulatory function is the Sertoli cell (SC), 
given its intimate contact with germ cells 
devoid of AR (17-19). Our findings 
endorse this assumption. Other rodent 
studies have revealed the major role played 
by SC AR in the completion of 
spermatogenesis (20). Several groups (1-3) 
recently generated mice with SC-selective 
AR knockout (SCARKO mice), opening 
up new possibilities to elucidate the 
respective contributions to 
spermatogenesis of AR expression in 
different testicular cell types. Thus, despite 
normal testicular descent, all SCARKO 
mice generated to date display arrested 
spermatogenesis. These results prove that 
the initiation and maintenance of 
spermatogenesis are both crucially 
dependent on AR activation in SC. Several 
authors, while studying the profile of AR 
expression in SC during post-natal 
development of normal rodents and non 
human primates (21-24), failed to detect 
immunochemical AR expression in the 
immediate post-natal period. This could 
explain why the elevated T levels present 
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in rodent and marmoset testis are unable to 
induce morphological maturation of SC, or 
to trigger and maintain spermatogenesis, 
despite high levels of androgens and 
gonadotropins in the fetus and neonate.  
The main purpose of the present study was 
to extend to humans this concept of a 
physiological state of transient androgen 
insensitivity of SC during fetal and 
neonatal life. Our results clearly show that, 
as reported for rodents and marmoset, AR 
protein is present in Leydig and peritubular 
cells of fetal and neonatal human testis, but 
not in SC. This expression pattern is in 
keeping with the absence of 
spermatogenesis, as expected (25-27), in 
our samples. During these two periods of 
human testicular development, hCG- and 
LH-induced biosynthesis of T is activated, 
as indicated by the strong 3βHSD 
expression in Leydig cells. This lack of AR 
expression in SC during early testicular 
development contrasted with the expected 
(17) strong AR expression we observed in 
these cells in sperm-producing adult 
human testis.  
The role of FSH in the initiation of human 
spermatogenesis remains controversial (15, 
28-32). In order to confirm that the lack of 
FSH receptor expression is not responsible 
for the lack of spermatogenic development 
in the fetal and early post-natal testis, we 
examined the FSHR expression pattern in 
SC in the same testicular samples. 
Immunochemical studies clearly showed 
FSHR expression in fetal and neonatal SC, 
as well as in adult SC. These findings, 
which concord with the FSHR transcript 
expression we also observed in human 
fetal testis, are also in line with the 
presence of FSH binding sites in fetal 
primate testis (33). It is generally accepted 
that FSH stimulates SC inhibin B (IB) 
secretion (4, 31, 34). Indeed, the presence 
of functional FSHR in human neonatal 
testis is suggested by two recent reports 
showing an increase in circulating IB in 
response to the neonatal rise in FSH (16, 
35). Collectively, these results rule out the 
possibility that the absence of 
spermatogenesis in fetal and neonatal life 
is due to a lack of FSHR. 
AMH, which is responsible for the 
repression of Mullerian ducts in male 
fetuses, is measurable in human male 
umbilical cord serum, as well as in the 
neonatal period and during infancy (36, 
37). The T elevation during puberty 
correlates with a fall in circulating AMH 
(6). This negative correlation is also 
observed in boys with central or 
gonadotropin-independent early puberty, 
suggesting that T is the main player in 
AMH down-regulation.  
Our combined T and AMH assays in 
umbilical cord, neonatal infants and adult 
blood provide additional in vivo support 
for the lack of functional AR expression in 
SC during the perinatal period. Indeed, the 
elevated T levels in fetal and neonatal 
males, in keeping with previous studies 
(16), are consistent with an increase in TT. 
However, AMH levels remained elevated 
during these two developmental stages, in 
keeping with the absence of AR in SC, as 
demonstrated here and in another very 
recent publication (25). Furthermore, 
circulating AMH levels were markedly 
increased in neonates compared to cord 
blood, owing to the reported FSH surge 
between these two periods (16, 38). This 
AMH increase is probably related to FSH-
induced SC proliferation (which increases 
the AMH-producing cell population), and 
also to activation of AMH gene 
transcription through a pathway mediated 
by cyclic AMP (15, 21). 
The negative correlation between testicular 
T and AMH levels is not found in neonatal 
rodents (21), human fetuses (6), or normal 
or cryptorchid human male newborns (16, 
37), indicating that testicular T is unable to 
repress AMH in the fetal and neonatal 
periods. In newborn rodents (21, 24) and in 
adult SCARKO mice (1), the absence of 
AR expression in SC is also associated 
with a lack of AMH repression, suggesting 
that a similar mechanism might exist in 
human male newborns. Our 
immunohistochemical findings 
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demonstrating strong AMH expression in 
SC lacking AR, and the marked fall 
observed in post-pubertal SC (which 
express AR) support this assumption. 
These results also argue against a 
mechanism in which a change in 
directional testicular AMH secretion (39) 
causes the fall in serum AMH after 
puberty.  
Patients with androgen insensitivity 
syndrome or CHH, a pathological 
condition associated with low testicular T, 
have abnormally elevated serum AMH 
levels. As we have previously shown (4, 5) 
the hCG-driven increase in intratesticular T 
in the 10 CHH patients studied here, was 
associated with a marked reduction in the 
serum AMH level. In contrast, AMH levels 
were not reduced in the two adult MAIS 
patients, who received the same combined 
gonadotropin treatment; on the contrary, 
they were markedly enhanced, in keeping 
with an absence of androgen action owing 
to the lack of AR signaling in SC. Thus, 
this AMH response pattern in MAIS is 
similar to that recently reported in two 
CHH neonates (35) receiving a similar 
treatment, indicating that in both cases the 
failure to repress AMH is related to the 
absence of functional AR expression in 
SC. 
In accordance to these in vivo findings, we 
obtained the first direct evidence that 
AMH repression by androgens only occurs 
when AR is expressed in Sertoli SMAT1 
cells. The molecular mechanisms 
underlying the repressive effect of AR on 
AMH expression remain to be elucidated. 
AR might directly repress AMH 
transcription even though no androgen 
response elements are present in the 
regulatory regions of the AMH gene. 
Alternatively, AR might compromise 
FSHR-mediated AMH stimulation by 
altering AP2 and NFκB signaling (15). We 
are currently investigating the functional 
interaction between AR and FSHR 
activation cascade on AMH expression 
using a Sertoli cell model.  
In conclusion, the absence of androgen 
receptor expression in Sertoli cells of fetal 
and neonatal human testis contributes to 
the lack of germ cell maturation and of 
anti-Mullerian hormone repression despite 
strong testicular testosterone biosynthesis. 
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FIGURE LEGENDS: 
Figure 1: Immunoexpression of 3βHSD, AR 
and AMH in human testis: 
Representative illustrations of 
immunoreactivity in fetal, neonatal and adult 
testis. 
A, B, C: Immunoexpression of 3βHSD in fetal 
(A), neonatal (B) and adult (C) testis: 
Enzyme expression is localized to the 
cytoplasm of Leydig cells (L) in fetal, newborn 
and adult testis. Sertoli cells and germ cells are 
negative. 
D, E, F: Immunoexpression of AR in fetal (D), 
newborn (E) and adult (F) testis. 
In fetal (D) and newborn testis (E), nuclear AR 
expression is restricted to Leydig cells (L) and 
myoid peritubular cells (arrows). Both Sertoli 
cells and germ cells are negative. In adult testis 
(F), AR expression is present in the nucleus of 
Leydig cells (L), myoid peritubular cells 
(arrows) and also Sertoli cells (arrowheads). 
G, H, I: Immunoexpression of AMH in fetal 
(G), newborn (H) and adult (I) testis 
AMH is strongly expressed in Sertoli cell 
cytoplasm in fetal (G) and newborn testis (H). 
AMH is undetectable in adult human testis.  
ST: seminiferous tubule 
Original magnification: x20.  
 
Figure 2: AMH and AR messenger levels in 
fetal human testis: 
A, B: Relative expression of AR (A) and AMH 
(B) mRNA in 10 fetal human testis obtained at 
16 (n=2), 20 (n=1), 21 (n=1), 22 (n=1), 24 
(n=2), 25 (n=2) and 38 (n=1) weeks of 
gestation. (See Supplemental Table 1 for 
primers). Results were normalized to 18S 
ribosomal RNA. Relative expression
 
in a given 
sample was calculated as attomoles
 
per 
femtomol of 18S RNA. Results are means ±
 
SEM of at least two RT samples run in 
duplicate, and represent the relative expression 
compared with control adult testes (arbitrarily 
1).
  
 
Figure 3: FSHR expression in human testis 
A-C: FSHR protein expression in human fetal 
(A), newborn (B) and adult testis (C). The 
receptor is expressed on the Sertoli cell 
membrane (arrows). Germ cells are negative.  
D: Representative FSHR mRNA expression in 
human adult and fetal testis at 28 and 35 
weeks. RNA was extracted and reverse 
transcribed as described in Material and 
Methods. (See Supplemental Table 1 for 
primers). A: Adult. RT- (omission of the 
reverse transcriptase) and H
2
O are negative 
controls.  
 
Figure 4: Relationship between AMH and 
testosterone levels in normal and androgen-
deficient human males: 
A: Left Panel: Time course of individual 
serum AMH levels (pmol/L) in two adult 
MAIS patients and mean (±SD) serum AMH 
in 10 adult CHH patients during combined 
gonadotropins stimulation (recombinant 
human FSH (rhFSH) and human chorionic 
gonadodotropin (hCG)). 
Right panel: Serum AMH levels (pmol/L) 
were measured in adult, neonatal (20 and 30 
post-natal days) and umbilical cord arterial 
bloods. Results are means ± SEM of at least 19 
values. ***, P <0.001 vs adult values, Mann-
Whitney test.. 
B: High AMH immunoexpression in testis of 
an untreated adult patient with congenital 
hypogonadic hypogonadotropism (CHH) and 
two adults with mild androgen insensitivity 
syndrome (AIS).  
  
 
Figure 5: Androgens repress endogenous 
AMH expression in SMAT1 Sertoli cells in 
the presence of AR:  
A: AR was expressed in SMAT1 cells 
transfected with pcDNA3-hAR plasmid. 
Proteins (0.5 mg) were immunoprecipitated 
(IP) with an anti-AR antibody, followed by 
Western blotting (WB) with the same 
antibody. AR protein was only expressed in 
SMAT1 cells transiently transfected with 
pcDNA3-hAR plasmid. 
B, C: Relative AMH expression was analyzed 
by using real-time PCR in control SMAT1 
cells (B) and in SMAT1 cells transiently 
transfected with pcDNA3-hAR plasmid (C). 
Cells were treated with 10
-5
M forskolin alone 
or combined with 10
-7
M dihydrotestosterone 
(DHT) for 24 h. Results are means ±
 
SEM of at 
least six independent determinations and 
represent the relative expression compared 
with basal levels in untreated cells (arbitrarily 
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set at 1).
 
***, P < 0.001 non parametric Mann-
Whitney test. NS: not significant 
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Table 1: Summary of AR and AMH immunoexpression in human testis 
Immunoexpression was classified as: 0: absent or not detectable; Moderate: + and Strong: ++ 
as described in (23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Fœtal 
N=46 
  
  
Newborn 
n =10 
  
  
 
Adult 
n =10 
 
  
 
Sertoli Leydig Peritubular Sertoli Leydig Peritubular Sertoli Leydig Peritubular 
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